share_log

8-K: Current report

8-K: Current report

8-K:重大事件
美股SEC公告 ·  2024/05/22 13:18

Moomoo AI 已提取核心訊息

Heart Test Laboratories, Inc., a company listed on the Nasdaq Capital Market, has announced that its delisting action by Nasdaq has been temporarily stayed. The stay is pending a final decision by a Nasdaq Hearing Panel following the company's appeal, which will be heard on June 27, 2024. The company had received a notice of delisting due to non-compliance with Nasdaq's Minimum Bid Price Requirement and Low Priced Stocks Rule, as its common stock had closed at $0.10 or less for ten consecutive trading days. Heart Test Laboratories had previously been granted an extension until July 29, 2024, to regain compliance with the Minimum Bid Price Requirement. In response to the delisting notice, the company implemented a 1-for-100 reverse stock split on...Show More
Heart Test Laboratories, Inc., a company listed on the Nasdaq Capital Market, has announced that its delisting action by Nasdaq has been temporarily stayed. The stay is pending a final decision by a Nasdaq Hearing Panel following the company's appeal, which will be heard on June 27, 2024. The company had received a notice of delisting due to non-compliance with Nasdaq's Minimum Bid Price Requirement and Low Priced Stocks Rule, as its common stock had closed at $0.10 or less for ten consecutive trading days. Heart Test Laboratories had previously been granted an extension until July 29, 2024, to regain compliance with the Minimum Bid Price Requirement. In response to the delisting notice, the company implemented a 1-for-100 reverse stock split on May 17, 2024. The company believes it has regained compliance with Nasdaq's listing requirements, but there is no guarantee that the appeal will be successful or that it will remain listed on Nasdaq. The company's common stock and public warrants will continue to trade on Nasdaq under the symbols 'HSCS' and 'HSCSW' respectively, pending the outcome of the hearing.
在納斯達克資本市場上市的公司Heart Test Laboratories, Inc. 宣佈,納斯達克的退市行動已暫時中止。該公司的上訴將於2024年6月27日審理後,納斯達克聽證會小組做出最終決定,該上訴將暫停審理。該公司因不遵守納斯達克的最低出價要求和低價股票規則而收到退市通知,因爲其普通股連續十個交易日收於0.10美元或以下。心臟測試實驗室此前已獲准延期至2024年7月29日,以恢復對最低出價要求的遵守。作爲對退市通知的回應,該公司於2024年5月17日實施了每100股的反向股票拆分。該公司認爲已恢復遵守納斯達克的上市要求,但無法保證上訴會成功或將繼續在納斯達克上市。在聽證會得出結果之前,該公司的普通股和公開認股權證將繼續在納斯達克交易,代碼分別爲 “HSCS” 和 “HSCSW”。
在納斯達克資本市場上市的公司Heart Test Laboratories, Inc. 宣佈,納斯達克的退市行動已暫時中止。該公司的上訴將於2024年6月27日審理後,納斯達克聽證會小組做出最終決定,該上訴將暫停審理。該公司因不遵守納斯達克的最低出價要求和低價股票規則而收到退市通知,因爲其普通股連續十個交易日收於0.10美元或以下。心臟測試實驗室此前已獲准延期至2024年7月29日,以恢復對最低出價要求的遵守。作爲對退市通知的回應,該公司於2024年5月17日實施了每100股的反向股票拆分。該公司認爲已恢復遵守納斯達克的上市要求,但無法保證上訴會成功或將繼續在納斯達克上市。在聽證會得出結果之前,該公司的普通股和公開認股權證將繼續在納斯達克交易,代碼分別爲 “HSCS” 和 “HSCSW”。
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息